Literature DB >> 22251700

Plasmacytoid dendritic cells lead the charge against tumors.

Sonia Jiménez-Baranda1, Inês Pires Silva, Nina Bhardwaj.   

Abstract

Imiquimod is a TLR agonist that is used as an antitumor agent, mainly against skin tumors. Its clinical benefits are well described in several studies; however, the mechanisms behind its antitumor effects are not completely understood. In this issue of the JCI, Drobits and colleagues demonstrate that topical application of imiquimod suppresses cutaneous melanoma by TLR7-dependent recruitment and transformation of plasmacytoid dendritic cells into killer cells; this occurs independently of conventional adaptive immune mechanisms.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22251700      PMCID： PMC3266799          DOI： 10.1172/JCI61345

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


  25 in total

1.  CCR6/CCR10-mediated plasmacytoid dendritic cell recruitment to inflamed epithelia after instruction in lymphoid tissues.

Authors:  Vanja Sisirak; Nelly Vey; Béatrice Vanbervliet; Thomas Duhen; Isabelle Puisieux; Bernhard Homey; Edward P Bowman; Giorgio Trinchieri; Bertrand Dubois; Dominique Kaiserlian; Sergio A Lira; Alain Puisieux; Jean-Yves Blay; Christophe Caux; Nathalie Bendriss-Vermare
Journal:  Blood       Date:  2011-09-21       Impact factor: 22.113

2.  Treatment of locally recurrent mucosal melanoma with topical imiquimod.

Authors:  Elizabeth C Smyth; Marisa Flavin; Melissa P Pulitzer; Ginger J Gardner; Peter D Costantino; Dennis S Chi; Kita Bogatch; Paul B Chapman; Jedd D Wolchok; Gary K Schwartz; Richard D Carvajal
Journal:  J Clin Oncol       Date:  2011-10-17       Impact factor: 44.544

Review 3.  Toll-like receptors and their crosstalk with other innate receptors in infection and immunity.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Immunity       Date:  2011-05-27       Impact factor: 31.745

Review 4.  Trafficking properties of plasmacytoid dendritic cells in health and disease.

Authors:  Silvano Sozzani; William Vermi; Annalisa Del Prete; Fabio Facchetti
Journal:  Trends Immunol       Date:  2010-06-25       Impact factor: 16.687

Review 5.  Toll-like receptor agonists: are they good adjuvants?

Authors:  Sacha Gnjatic; Nikhil B Sawhney; Nina Bhardwaj
Journal:  Cancer J       Date:  2010 Jul-Aug       Impact factor: 3.360

6.  In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.

Authors:  Joshua D Brody; Weiyun Z Ai; Debra K Czerwinski; James A Torchia; Mia Levy; Ranjana H Advani; Youn H Kim; Richard T Hoppe; Susan J Knox; Lewis K Shin; Irene Wapnir; Robert J Tibshirani; Ronald Levy
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

7.  Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells.

Authors:  Barbara Drobits; Martin Holcmann; Nicole Amberg; Melissa Swiecki; Roland Grundtner; Martina Hammer; Marco Colonna; Maria Sibilia
Journal:  J Clin Invest       Date:  2012-01-17       Impact factor: 14.808

8.  CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis.

Authors:  Bin-Zhi Qian; Jiufeng Li; Hui Zhang; Takanori Kitamura; Jinghang Zhang; Liam R Campion; Elizabeth A Kaiser; Linda A Snyder; Jeffrey W Pollard
Journal:  Nature       Date:  2011-06-08       Impact factor: 49.962

9.  Mast cells are crucial for early inflammation, migration of Langerhans cells, and CTL responses following topical application of TLR7 ligand in mice.

Authors:  Valeska Heib; Marc Becker; Tobias Warger; Gerd Rechtsteiner; Christine Tertilt; Matthias Klein; Tobias Bopp; Christian Taube; Hansjörg Schild; Edgar Schmitt; Michael Stassen
Journal:  Blood       Date:  2007-04-19       Impact factor: 22.113

10.  Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells.

Authors:  Mercedes B Fuertes; Aalok K Kacha; Justin Kline; Seng-Ryong Woo; David M Kranz; Kenneth M Murphy; Thomas F Gajewski
Journal:  J Exp Med       Date:  2011-09-19       Impact factor: 14.307
View more
  2 in total

Review 1.  Plasmacytoid dendritic cells in HIV infection.

Authors:  Meagan O'Brien; Olivier Manches; Nina Bhardwaj
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

2.  Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist.

Authors:  Lyudmila G Burdelya; Craig M Brackett; Bojidar Kojouharov; Ilya I Gitlin; Katerina I Leonova; Anatoli S Gleiberman; Semra Aygun-Sunar; Jean Veith; Christopher Johnson; Gary J Haderski; Patricia Stanhope-Baker; Shyam Allamaneni; Joseph Skitzki; Ming Zeng; Elena Martsen; Alexander Medvedev; Dmitry Scheblyakov; Nataliya M Artemicheva; Denis Y Logunov; Alexander L Gintsburg; Boris S Naroditsky; Sergei S Makarov; Andrei V Gudkov
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-29       Impact factor: 11.205
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.